Albuvirtide

DRUG5 trials

Sponsors

Frontier Biotechnologies Inc.

Conditions

AIDSHIV InfectionsHIV-1-infectionHIV/AIDS

Phase 1

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

CompletedNCT05206019

Frontier Biotechnologies Inc.HIV/AIDS

Start: 2022-02-16End: 2022-05-02Updated: 2023-01-09

Phase 2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Frontier Biotechnologies Inc.HIV-1-infection

Start: 2018-12-17End: 2022-12-31Target: 80Updated: 2021-09-29

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Frontier Biotechnologies Inc.HIV/AIDS

Start: 2021-11-30End: 2022-12-01Target: 20Updated: 2021-09-29

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Frontier Biotechnologies Inc.HIV/AIDS

Start: 2021-05-01End: 2022-12-01Target: 24Updated: 2021-03-26

Phase 3

Test Albuvirtide in Experienced Patients

CompletedNCT02369965

Frontier Biotechnologies Inc.AIDS, HIV Infections

Start: 2014-02-19End: 2018-04-02Updated: 2021-10-06

Related Papers

Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.

2026-03-28

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

Chinese Medical Journal2020-11-2544 citations